Esperite N.V. (ESP) with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of Bronchopulmonary Dysplasia.
27 févr. 2019 01h17 HE
|
Esperite N.V.
CF-MEV-132 drug candidate belongs to the CF-MEV family of anti-inflammatory EV drugs produced by The Cell Factory Amsterdam, The Netherlands – 27 February 2019 The Cell Factory and the...
ESPERITE (ESP) announces private placement of convertible loan notes to the European Select Growth Opportunities Fund
26 févr. 2019 01h17 HE
|
Esperite N.V.
Amsterdam, The Netherlands – 26 February 2019 Esperite N.V. (Euronext: ESP, “Esperite”) announces today a EUR 280,000 private placement of 28 convertible notes with a principal amount of EUR 10,000...
ESPERITE NV (ESP) AND PBKM (FAMICORD GROUP) SIGN EXCLUSIVE AGREEMENT REGARDING POTENTIAL ACQUISITION OF CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS.
22 févr. 2019 01h17 HE
|
Esperite N.V.
Amsterdam, the Netherlands – 22 February 2019 Esperite N.V. (Euronext: ESP) and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM) are pleased to announce that they have entered into an...
ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 24th tranche of investment today
10 janv. 2019 01h17 HE
|
Esperite N.V.
Amsterdam, The Netherlands - 10 January 2019 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 24th Tranche of EUR 230,000 is issued as a private placement of 23...
Hybrigenics (ALHYG) : Moonstone Investments a soumis une proposition de transaction, sous conditions suspensives.
03 déc. 2018 14h11 HE
|
Esperite N.V.
Cette proposition, crédible et créatrice de valeur, vise à donner un nouvel espoir à la société Hybrigenics et ses actionnaires et constitue une alternative à la dissolution anticipée. Amsterdam,...
ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 23rd tranche of investment today
30 nov. 2018 01h17 HE
|
Esperite N.V.
Amsterdam, The Netherlands - 30 November 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 23rd Tranche of EUR 220,000 is issued as a private placement of 22...
Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.
29 nov. 2018 01h17 HE
|
Esperite N.V.
This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn's, Bronchopulmonary dysplasia, Epilepsy and Stroke ...
ESPERITE N.V. convenes Annual General Meeting of Shareholders
27 nov. 2018 12h26 HE
|
Esperite N.V.
Amsterdam, the Netherlands - 27 November 2018 Esperite N.V. (Euronext: ESP, "Esperite") announces that it has convened its Annual General Meeting of Shareholders ("AGM") to be held on 8 January...
ESPERITE (ESP): financial results for 2017 are published.
23 nov. 2018 17h34 HE
|
Esperite N.V.
Amsterdam, The Netherlands - 23 November 2018 ESPERITE N.V. (Euronext: ESP, "Esperite", "the Company" or "the Group") has published today its Annual Report for the year ended 31 December 2017....
ESPERITE (ESP) announces publication of its Annual Report 2017 before 24 November 2018
19 nov. 2018 09h35 HE
|
Esperite N.V.
Amsterdam, The Netherlands - 19 November 2018 Esperite announces that the preparation of its Annual Report 2017 is now under final review by its auditors and should be published before 24...